858 results on '"Ishioka, Chikashi"'
Search Results
2. Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)
3. TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts
4. Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types
5. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility
6. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer
7. Aurora A polyubiquitinates the BRCA1-interacting protein OLA1 to promote centrosome maturation
8. Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer
9. Factors related to specialized palliative care use and aggressive care at end of life in Japanese patients with advanced solid cancers: a cohort study
10. Application of targeted nanopore sequencing for the screening and determination of structural variants in patients with Lynch syndrome
11. TP53 signature diagnostic system using multiplex reverse transcription–polymerase chain reaction system enables prediction of prognosis of breast cancer patients
12. Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case Report
13. Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome, endometrial cancer, and ovarian cancer
14. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial
15. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers
16. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
17. Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR).
18. Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors
19. Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer
20. MO10-2 Clinical decisions by the Molecular Tumor Board on comprehensive genomic profiling tests in Japan: A retrospective observational study
21. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
22. Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model
23. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma.
24. Comparison of efficacy and safety between carboplatin-etoposide and cisplatin-etoposide combination therapy in patients with advanced neuroendocrine carcinoma, retrospective study
25. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma
26. RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells
27. Distinct role of CD8 cells and CD4 cells in antitumor immunity triggered by cell apoptosis using a Herpes simplex virus thymidine kinase/ganciclovir system
28. Preferred and actual places of death among patients with advanced cancer: A single-center cohort study in Japan
29. Understanding the Function-Structure and Function-Mutation Relationships of p53 Tumor Suppressor Protein by High-Resolution Missense Mutation Analysis
30. Detection of ATM Gene Mutation in Human Glioma Cell Line M059J by a Rapid Frameshift/Stop Codon Assay in Yeast
31. Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers
32. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
33. Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum
34. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors
35. Abstract 6389: Differential role of CD8 cells and CD4 cells in anti-tumor immunity triggered by tumor cell apoptosis using HSVtk/GCV system
36. Figure S2 from BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number
37. Data from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
38. Supplementary Figure 2 from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
39. Supplementary Figure 1 from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
40. Supplemental Table 2 from BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number
41. Supplemental Table 1 from BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number
42. Supplementary Figure 3 from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
43. Data from BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number
44. Supplementary Figure Legend from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
45. Supplementary Figure 1 from Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
46. Supplementary Table 1 from Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
47. Supplementary Figure 5 from Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
48. Supplementary Figure 3 from Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
49. Supplementary Figure 4 from Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
50. Supplementary Figures S1-S6 from Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.